
Novocure (NVCR) Stock Forecast & Price Target
Novocure (NVCR) Analyst Ratings
Bulls say
NovoCure Ltd is positioned for potential revenue acceleration due to a recent study that may allow Glioblastoma (GBM) patients to start treatment 2-3 months earlier, which could increase revenue per patient by approximately 20-30%. The company anticipates growth in active patients, particularly in the United States and Germany, which is expected to serve as a leading indicator for revenue growth through 2026. Additionally, NovoCure is expected to begin seeing incremental revenue from new markets within the next 12-18 months, further enhancing its revenue growth drivers.
Bears say
NovoCure Ltd is projected to experience a significant decline in EBITDA as revenue growth gradually increases over the forthcoming quarters, which is anticipated to ultimately reach breakeven levels by 2027. The reliance on a slow ramp-up in revenues raises concerns regarding the company’s ability to manage operating costs effectively in the interim. Additionally, this extended timeline to reach EBITDA breakeven may indicate ongoing financial strain and uncertainty regarding the commercialization success of its Tumor Treating Fields devices and pipeline products.
This aggregate rating is based on analysts' research of Novocure and is not a guaranteed prediction by Public.com or investment advice.
Novocure (NVCR) Analyst Forecast & Price Prediction
Start investing in Novocure (NVCR)
Order type
Buy in
Order amount
Est. shares
0 shares